Research

March 19, 2025 Earlier this month, CervoMed Pharmaceuticals reported data from an open-label extension phase of the RewinD-LB trial suggesting that the study drug, neflamapimod, may slow cognitive decline in […]

January 5, 2025 A new research paper from Mayo Clinic and the Karolinska Institutet suggests that the brain’s energy use levels decline measurably early in the course of the disease. […]

December 18, 2024 This week Cognition Therapeutics reported encouraging topline results from their Phase 2 clinical trial of CT1812, an investigational drug being studied in people with dementia with Lewy […]

November 14, 2024 Clinical trial results reported at a recent scientific conference suggest that the drug nilotinib may improve outcomes in people with dementia with Lewy bodies (DLB). Nilotinib is […]

November 5, 2024 2024 has been an exciting year for clinical trials for people with Lewy body dementia (LBD). Over the past year, you have heard a lot from the […]

September 26, 2024 A new study published in the medical research journal Neurology suggests that sudden worsening of kidney function (referred to as “acute kidney injury”) may nearly double the […]

September 04, 2024 Clinical trials are the key to unlocking future treatments and preventive strategies for Lewy body dementia (LBD). Only by testing new medications in controlled experiments, called trials, […]

August 05, 2024 According to new research from the University of Iowa, medications used for prostate enlargement may provide clues to future strategies to prevent dementia with Lewy bodies (DLB). […]

May 29, 2024 Many people who have dementia with Lewy bodies (DLB) experience delay and difficulty with receiving an accurate diagnosis, often seeing multiple specialists before being correctly diagnosed. In […]

March 18, 2024 Hallucinations and delusions (also called psychosis) are prominent features of Lewy body dementia (LBD), occurring in both dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). […]